To review the existing data on use of the rifamycin class of antibiotics as therapy for Clostridium difficile–associated diarrhea (CDAD).
Data Sources:
A literature search was performed using PubMed (1996–January 2008), abstracts from the International Conference on Antimicrobial Agents and Chemotherapy (September 2007), the Infectious Diseases Society of America (October 2007), Salix Pharmaceuticals Web site (January 2008), ActivBiotics Web site (January 2008). Google Scholar, and searches of selected bibliographies using the terms rifamycin, ansamycins, rifampin, rifabutin, rifampicin, rifaximin, rifalazil, Clostridium difficile, C. difficile, and CDAD.
Study Selection and Data Extraction:
In vivo and in vitro studies investigating the use of rifamycins for CDAD were selected, along with all clinical trials using rifamycins in patients with CDAD.
Data Synthesis:
Nine studies totaling 890 isolates were identified that investigated the in vitro susceptibility of rifampin (6 studies), rifaximin (3 studies), and rifalazil (2 studies). Rifamycins consistently displayed potent activity against tested strains, although strains with decreased susceptibility have been identified. Six published clinical studies involving 81 patients have investigated the use of rifamycins for the treatment of CDAD. These have generally been small studies, although initial positive clinical results have been reported on the use of rifamycins for recurrent CDAD.
Conclusions:
Preliminary data support the use of rifamycins for treatment of CDAD. With the increased incidence and severity of CDAD, further investigation into this drug class as a treatment regimen for CDAD is warranted.
AslamS, HamillRJ, MusherDM. Treatment of Clostridium difficile–associated disease: old therapies and new strategies. Lancet Infect Dis2005;5:549-57.
3.
SurowiecD, KuyumjianAG, WyndMA, CicognaCE. Past, present, and future therapies for Clostridium difficile–associated disease. Ann Pharmacother2006;40:2155-63. Epub 5 Dec 2006. DOI 10.1345/aph.1H332
AntonPM, O'brienM, KokkotouE. Rifalazil treats and prevents relapse of Clostridium difficile–associated diarrhea in hamsters. Antimicrob Agents Chemother2004;48:3975-9.
6.
BaconAE, McGrathS, FeketyR, HollowayWJ. In vitro synergy studies with Clostridium difficile. Antimicrob Agents Chemother1991;35:582-3.
7.
BisharaJ, BlochY, GartyM, BehorJ, SamraZ.Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis2006;54:141-4.
8.
BourgaultAM, LamotheF, LooVG, PoirierL.In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother2006;50:3473-5.
9.
HechtDW, GalangMA, SambolSP, OsmolskiJR, JohnsonS, GerdingDN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother2007;51:2716-9.
10.
MarcheseA, SalernoA, PesceA, DebbiaEA, SchitoGC. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy2000;46:253-66.
11.
RipaS, MigniniF, PrennaM, FalcioniE.In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp Clin Res1987;13:483-8.
12.
EnsmingerPW, CounterFT, ThomasLJ, LubbehusenPP. Susceptibility, resistance development, and synergy of antimicrobial combinations against Clostridium difficile. Curr Microbiol1982;7:59-62.
13.
BarbutF, DecreD, BurghofferB. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother1999;43:2607-11.
14.
HallMJ, MiddletonRF, WestmacottD.The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother1983;11:427-33.
15.
JiangZD, KeS, PalazzineE. In vitro activity and fecal concentrations of rifaximin after oral administration. Antimicrob Agents Chemother2000;44:2205-6.
16.
BurmanWJ, GallicanoK, PeloquinC.Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet2001;40:327-41.
17.
GerardL, GareyKW, DuPontHL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther2005;3:201-11.
18.
RothsteinDM, ShalishC, MurphyCK, SternlichtA, CampbellLA. Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin Investig Drugs2006;15:603-23.
19.
WilliamsR, BassN.Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord2005;5(suppl 1):S10-8.
20.
DescombeJJ, DubourgD, PicardM, PalazziniE.Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res1994;14:51-6.
21.
GionchettiP, RizzelloF, FerrieriA. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind, placebo-controlled trial. Dig Dis Sci1999;44:1220-1.
22.
RizzelloF, GionchettiP, VenturiA. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol1998;54:91-3.
BoltonRP, CulshawMA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut1986;27:1169-72.
25.
PentikisHS, ConnollyM, TrapnellCB, ForbesWP, BettenhausenDK. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy2007;27:1361-9.
26.
HosoeK, MaeT, KonishiE. Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob Agents Chemother1996;40:2749-55.
27.
MaeT, HosoeK, YamamotoT. Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica1998;28:759-66.
28.
KokkotouE, MustafaN, O'brienM, PothoulakisC, KellyCP. Rifaximin: a novel nonabsorbed antibiotic therapy for Clostridium difficile–associated diarrhea. Presented at: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16–19, Washington, DC. 2005.
29.
NomuraK, MatsumotoY, YoshidaN. Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin's lymphoma. World J Gastroenterol2004;10:765-6.
30.
BuggyBP, FeketyR, SilvaJJr.. Therapy of relapsing Clostridium difficile–associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol1987;9:155-9.
31.
GareyKW, JiangZD, BellardA, DuPontHL. Rifaximin in treatment of recurrent Clostridium difficile associated diarrhea, an uncontrolled pilot study. J Clin Gastroenterol 2008 (Epub ahead of print).
32.
JohnsonS, SchrieverC, GalangM, KellyCP, GerdingDN. Interruption of recurrent Clostridium difficile–associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis2007;44:846-8.
33.
BoeroM, BertiE, MorgandoA, VermeG.Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs. vancomycin. Microbiologia Medica1990;5:74-7.
34.
LagrotteriaD, HolmesS, SmiejaM, SmaillF, LeeC.Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile–associated diarrhea. Clin Infect Dis2006;43:547-52.
35.
BorielloSP, JonesRH, PhillipsI.Rifampicin-associated pseudomembranous colitis. Br Med J1980;281:1180-1.
36.
ByrdRPJr, RoyTM, OssorioMA, FieldsCL. Delayed onset of pseudomembranous colitis after rifampin therapy. South Med J1997;90:644-6.
37.
FournierG, OrgiazziJ, LenoirB, DechavanneM.Pseudomembranous colitis probably due to rifampicin. Lancet1980;1:101.
O'ConnorRP, SilvaJJr, FeketyR.Rifampicin and antibiotic-associated colitis. Lancet1981;1:499.
40.
ChenYX, CabanaB, KivelN, MichaelisA.Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers. J Clin Pharmacol2007;47:841-9.
41.
WilliamsR, JamesOF, WarnesTW, MorganMY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol2000;12:203-8.
